Davis Matthew W. sold $26K of AQST
Davis Matthew W. (Chief Development Officer) sold 7,197 shares of Aquestive Therapeutics, Inc. (AQST) at $3.55 on 2026-11-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides transparency on insider selling activity, but it does not introduce new company fundamentals (no earnings, guidance, trial results, or regulatory decisions).
Market read
For AQST, this is primarily a sentiment/positioning datapoint rather than a catalyst.
What to watch
Traders may over-weight insider-sale optics; without accompanying operational updates, the filing is unlikely to change fundamental valuation.
Background
The article is an SEC Form 4 insider transaction disclosure for Aquestive Therapeutics (AQST).
Ticker impact
Aquestive Therapeutics insider Davis Matthew W., Chief Development Officer, sold 7,197 shares at $3.5468 on a 10b5-1 plan, per Form 4 filed today.
Shares may face slight overhead from the optics of an insider sale, but the 10b5-1 plan makes a large price reaction less likely.
The filing is a primary SEC Form 4 disclosure with a modest transaction size and explicit 10b5-1 pre-arrangement, which typically dampens market interpretation.
Market effects
Minimal, as this is a single-company insider transaction without new clinical, regulatory, or financial guidance.
None.
None.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerAquestive Therapeutics, Inc.
US-listed biotech subject of the Form 4 insider sale disclosure.
- insiderDavis Matthew W.
Chief Development Officer who sold shares under a Rule 10b5-1 plan.


